Device Trial Radar · NCT04078243
Feasibility of Novel Clinical Trial Infrastructure, Design and Technology for Early Phase Studies in Patients With Pulmonary Hypertension (FIT-PH)
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jan 21, 2020
Primary completion
Jan 6, 2028
Study completion Sep 6, 2028
Sponsor
- Lead sponsor
- Sheffield Teaching Hospitals NHS Foundation TrustAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 6, 2019
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Prospective, open-label, observational study to evaluate the safety and feasibility of using pulmonary artery pressure (PAP) monitors and wearable activity monitors in patients with pulmonary hypertension (PH).
Conditions
- Pulmonary Hypertension
Interventions
CardioMEMS HF SystemDevice
The CardioMEMS HF System is the first and only FDA-approved wireless heart failure monitor. The system is a safe, reliable way to help your patients manage their heart failure.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Activity MonitorsTime frame: Through study completion - 30/03/2024
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, South Yorkshire, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.